Geron | GERN - Ordinary Share Capital


Geron reported $640.9M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Amgen USD 540M 1000K Mar/2026
Bio Techne USD 156.45M 703K Mar/2026
Cassava Sciences USD 48.31M 0 Dec/2025
Cytokinetics USD 124.43M 2.17M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Exelixis USD 253.7M 8.78M Mar/2026
Genmab DKK 61.62M 52K Dec/2025
Geron USD 640.9M 2.54M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
MacroGenics USD 63.32M 60K Dec/2025
Novartis USD 1.91B 60K Mar/2026
Novavax USD 162.58M 106K Dec/2025